हाइड्रोकोडोन और पैरासिटामोल के इंटरैक्शन

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

In addition, discontinuation of a concomitantly used Cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentrations. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

In addition, discontinuation of a concomitantly used Cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentrations. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

…BITARTRATE AND ACETAMINOPHEN TABLETS Addiction, Abuse, and Misuse Because the use of hydrocodone bitartrate and acetaminophen tablets expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of… (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और पैरासिटामोल लेबल, सावधानियां)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और पैरासिटामोल लेबल, सावधानियां)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Alvimopan capsules are contraindicated in patients who have taken therapeutic doses of opioids for more than 7 consecutive days immediately prior to taking alvimopan capsules [see Warnings and Precautions ( 5.3 )]. (एल्विमोपैन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Hypersensitivity Reactions Serious acute hypersensitivity reactions; including fatal or life-threatening anaphylaxis, rash, hypotension, wheezing, and/or shortness of breath; have been observed in patients receiving intravenous acetylcysteine for acetaminophen overdose and occurred soon after initiation of the infusion [ see Adverse Reactions ( 6 ) ]. (एसिटाइलसिस्टीन लेबल, चेतावनियां और सावधानियां)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और पैरासिटामोल लेबल, सावधानियां)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

…BITARTRATE AND ACETAMINOPHEN TABLETS Addiction, Abuse, and Misuse Because the use of hydrocodone bitartrate and acetaminophen tablets expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of… (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

…BITARTRATE AND ACETAMINOPHEN TABLETS Addiction, Abuse, and Misuse Because the use of hydrocodone bitartrate and acetaminophen tablets expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of… (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

…BITARTRATE AND ACETAMINOPHEN TABLETS Addiction, Abuse, and Misuse Because the use of hydrocodone bitartrate and acetaminophen tablets expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of… (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और पैरासिटामोल लेबल, सावधानियां)

…BITARTRATE AND ACETAMINOPHEN TABLETS Addiction, Abuse, and Misuse Because the use of hydrocodone bitartrate and acetaminophen tablets expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of… (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

• Avoid concurrent use of alcohol or other central nervous system depressants with olopatadine hydrochloride nasal solution (nasal spray) ( 5.2 ). (ओलोपाटाडीन लेबल, चेतावनियां और सावधानियां)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with RYALTRIS because additional reductions in alertness and additional impairment of CNS performance may occur. (ओलोपाटाडीन और मोमेटासोन लेबल, चेतावनियां और सावधानियां)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

BOXED WARNING Ketorolac tromethamine tablets, a nonsteroidal anti-inflammatory drug (NSAID), are indicated for the short-term (up to 5 days in adults), management of moderately severe acute pain that requires analgesia at the opioid level and only as continuation treatment following IV or IM dosing of ketorolac tromethamine, if necessary. (कीटोरोलैक लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

…BITARTRATE AND ACETAMINOPHEN TABLETS Addiction, Abuse, and Misuse Because the use of hydrocodone bitartrate and acetaminophen tablets expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of… (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

In addition, discontinuation of a concomitantly used Cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentrations. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और पैरासिटामोल लेबल, सावधानियां)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और पैरासिटामोल लेबल, सावधानियां)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

…BITARTRATE AND ACETAMINOPHEN TABLETS Addiction, Abuse, and Misuse Because the use of hydrocodone bitartrate and acetaminophen tablets expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of… (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

…BITARTRATE AND ACETAMINOPHEN TABLETS Addiction, Abuse, and Misuse Because the use of hydrocodone bitartrate and acetaminophen tablets expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of… (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

…BITARTRATE AND ACETAMINOPHEN TABLETS Addiction, Abuse, and Misuse Because the use of hydrocodone bitartrate and acetaminophen tablets expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of… (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

The use of hydrocodone bitartrate and acetaminophen tablets is not recommended for patients taking MAOIs or within 14 days of stopping such treatment. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

CONTRAINDICATIONS Diphenoxylate hydrochloride and atropine sulfate is contraindicated in: • Pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (CNS) depression (see WARNINGS ). (डाइफेनोक्सिलेट और एट्रोपिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और पैरासिटामोल लेबल, सावधानियां)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और पैरासिटामोल लेबल, सावधानियां)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और पैरासिटामोल लेबल, सावधानियां)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और पैरासिटामोल लेबल, सावधानियां)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

In addition, discontinuation of a concomitantly used Cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentrations. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

In addition, discontinuation of a concomitantly used Cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentrations. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और पैरासिटामोल लेबल, सावधानियां)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और पैरासिटामोल लेबल, सावधानियां)

Additionally, avoid the use of mixed agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) or partial agonist (e.g., buprenorphine) analgesics in patients who are receiving a full opioid agonist analgesic, including hydrocodone bitartrate and acetaminophen tablets. (हाइड्रोकोडोन और पैरासिटामोल लेबल, चेतावनियां)

…concomitantly using strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) because these medications can significantly increase exposure to naloxegol which may precipitate opioid withdrawal symptoms such as hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, irritability, and yawning [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)… (नालोक्सेगोल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated. (नालोक्सोन लेबल, चेतावनियां और सावधानियां)

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (नाल्ट्रेक्सोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…limited to, WELLBUTRIN, WELLBUTRIN SR, WELLBUTRIN XL, APLENZIN and ZYBAN) Bulimia or anorexia nervosa, which increase the risk for seizure [see Warnings and Precautions (5.3) ] Chronic opioid or opiate agonist (e.g., methadone) or partial agonists (e.g., buprenorphine) use, or acute opiate withdrawal [see Warnings and Precautions (5.4) and Drug Interactions (7.2)… (नाल्ट्रेक्सोन और ब्यूप्रोपियॉन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Intervention Avoid use of SYMPROIC with another opioid antagonist. (नाल्डेमेडिन लेबल, दवाओं के इंटरैक्शन)

Risk of Recurrent Respiratory and CNS Depression : A recurrence of respiratory depression is possible, therefore, keep the patient under continued surveillance and administer repeat doses of ZURNAI using a new auto-injector with each dose while awaiting emergency medical assistance. (नाल्मेफीन लेबल, चेतावनियां और सावधानियां)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

In addition, discontinuation of a concomitantly used Cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentrations. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

In addition, discontinuation of a concomitantly used Cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentrations. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Additionally, avoid the use of mixed agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) or partial agonist (e.g., buprenorphine) analgesics in patients who are receiving a full opioid agonist analgesic, including hydrocodone bitartrate and acetaminophen tablets. (हाइड्रोकोडोन और पैरासिटामोल लेबल, चेतावनियां)

…BITARTRATE AND ACETAMINOPHEN TABLETS Addiction, Abuse, and Misuse Because the use of hydrocodone bitartrate and acetaminophen tablets expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of… (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

…BITARTRATE AND ACETAMINOPHEN TABLETS Addiction, Abuse, and Misuse Because the use of hydrocodone bitartrate and acetaminophen tablets expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of… (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और पैरासिटामोल लेबल, सावधानियां)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और पैरासिटामोल लेबल, सावधानियां)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और पैरासिटामोल लेबल, सावधानियां)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

…BITARTRATE AND ACETAMINOPHEN TABLETS Addiction, Abuse, and Misuse Because the use of hydrocodone bitartrate and acetaminophen tablets expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of… (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

…BITARTRATE AND ACETAMINOPHEN TABLETS Addiction, Abuse, and Misuse Because the use of hydrocodone bitartrate and acetaminophen tablets expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of… (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

The use of hydrocodone bitartrate and acetaminophen tablets is not recommended for patients taking MAOIs or within 14 days of stopping such treatment. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और पैरासिटामोल लेबल, सावधानियां)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और पैरासिटामोल लेबल, सावधानियां)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और पैरासिटामोल लेबल, सावधानियां)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और पैरासिटामोल लेबल, सावधानियां)

Opioid Antagonist: Naloxegol ↑ naloxegol Avoid use with BIXLENVO; if unavoidable, decrease the dosage of naloxegol and monitor for adverse reactions. (बिक्टेग्राविर, एमट्रिसिटाबिन और टेनोफोविर एलाफेनामाइड लेबल, दवाओं के इंटरैक्शन)

…BITARTRATE AND ACETAMINOPHEN TABLETS Addiction, Abuse, and Misuse Because the use of hydrocodone bitartrate and acetaminophen tablets expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of… (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

In addition, discontinuation of a concomitantly used Cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentrations. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

…BITARTRATE AND ACETAMINOPHEN TABLETS Addiction, Abuse, and Misuse Because the use of hydrocodone bitartrate and acetaminophen tablets expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of… (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

…BITARTRATE AND ACETAMINOPHEN TABLETS Addiction, Abuse, and Misuse Because the use of hydrocodone bitartrate and acetaminophen tablets expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of… (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Additionally, avoid the use of mixed agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) or partial agonist (e.g., buprenorphine) analgesics in patients who are receiving a full opioid agonist analgesic, including hydrocodone bitartrate and acetaminophen tablets. (हाइड्रोकोडोन और पैरासिटामोल लेबल, चेतावनियां)

Additionally, avoid the use of mixed agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) or partial agonist (e.g., buprenorphine) analgesics in patients who are receiving a full opioid agonist analgesic, including hydrocodone bitartrate and acetaminophen tablets. (हाइड्रोकोडोन और पैरासिटामोल लेबल, चेतावनियां)

Additionally, avoid the use of mixed agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) or partial agonist (e.g., buprenorphine) analgesics in patients who are receiving a full opioid agonist analgesic, including hydrocodone bitartrate and acetaminophen tablets. (हाइड्रोकोडोन और पैरासिटामोल लेबल, चेतावनियां)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

In addition, discontinuation of a concomitantly used Cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentrations. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

In addition, discontinuation of a concomitantly used Cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentrations. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

• Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (मिथाइलनाल्ट्रेक्सोन लेबल, दवाओं के इंटरैक्शन)

The use of hydrocodone bitartrate and acetaminophen tablets is not recommended for patients taking MAOIs or within 14 days of stopping such treatment. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और पैरासिटामोल लेबल, सावधानियां)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Acetaminophen: Avoid concomitant use with Metopirone. (मेटाइरापोन लेबल, दवाओं के इंटरैक्शन)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

…BITARTRATE AND ACETAMINOPHEN TABLETS Addiction, Abuse, and Misuse Because the use of hydrocodone bitartrate and acetaminophen tablets expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of… (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

…BITARTRATE AND ACETAMINOPHEN TABLETS Addiction, Abuse, and Misuse Because the use of hydrocodone bitartrate and acetaminophen tablets expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of… (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

In addition, discontinuation of a concomitantly used Cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentrations. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

The use of hydrocodone bitartrate and acetaminophen tablets is not recommended for patients taking MAOIs or within 14 days of stopping such treatment. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और पैरासिटामोल लेबल, सावधानियां)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

In addition, discontinuation of a concomitantly used Cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentrations. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

In addition, discontinuation of a concomitantly used Cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentrations. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

In addition, discontinuation of a concomitantly used Cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentrations. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

…BITARTRATE AND ACETAMINOPHEN TABLETS Addiction, Abuse, and Misuse Because the use of hydrocodone bitartrate and acetaminophen tablets expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of… (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और पैरासिटामोल लेबल, सावधानियां)

The use of hydrocodone bitartrate and acetaminophen tablets is not recommended for patients taking MAOIs or within 14 days of stopping such treatment. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

…BITARTRATE AND ACETAMINOPHEN TABLETS Addiction, Abuse, and Misuse Because the use of hydrocodone bitartrate and acetaminophen tablets expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of… (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और पैरासिटामोल लेबल, सावधानियां)

Avoid concurrent use of alcohol or other central nervous system depressants with XYZAL. (लेवोसेटिरिज़िन लेबल, चेतावनियां और सावधानियां)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

In addition, discontinuation of a concomitantly used Cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentrations. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और पैरासिटामोल लेबल, सावधानियां)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और पैरासिटामोल लेबल, सावधानियां)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और पैरासिटामोल लेबल, सावधानियां)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और पैरासिटामोल लेबल, सावधानियां)

Because respiratory depression may be greater than otherwise expected, decrease the dosage of hydrocodone bitartrate and acetaminophen tablets and/or the muscle relaxant (e.g., cyclobenzaprine, metaxalone) as necessary. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और पैरासिटामोल लेबल, सावधानियां)

Table 8: Drugs That are Affected by and Affecting Ciprofloxacin Drugs That are Affected by Ciprofloxacin Drug(s) Recommendation Comments Tizanidine Contraindicated Concomitant administration of tizanidine and ciprofloxacin is contraindicated due to the potentiation of hypotensive and sedative effects of tizanidine [see Contraindications ( 4.2 )]. (सिप्रोफ्लॉक्सासिन लेबल, दवाओं के इंटरैक्शन)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

In addition, discontinuation of a concomitantly used Cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentrations. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और पैरासिटामोल लेबल, सावधानियां)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और पैरासिटामोल लेबल, सावधानियां)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Avoid concurrent use of QUZYTTIR with alcohol or other CNS depressants because additional reduction in alertness and additional impairment of CNS performance may occur. (सेटिरिज़िन लेबल, चेतावनियां और सावधानियां)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

The use of hydrocodone bitartrate and acetaminophen tablets is not recommended for patients taking MAOIs or within 14 days of stopping such treatment. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और पैरासिटामोल लेबल, सावधानियां)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

…BITARTRATE AND ACETAMINOPHEN TABLETS Addiction, Abuse, and Misuse Because the use of hydrocodone bitartrate and acetaminophen tablets expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of… (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

…BITARTRATE AND ACETAMINOPHEN TABLETS Addiction, Abuse, and Misuse Because the use of hydrocodone bitartrate and acetaminophen tablets expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of… (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

…BITARTRATE AND ACETAMINOPHEN TABLETS Addiction, Abuse, and Misuse Because the use of hydrocodone bitartrate and acetaminophen tablets expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of… (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

…BITARTRATE AND ACETAMINOPHEN TABLETS Addiction, Abuse, and Misuse Because the use of hydrocodone bitartrate and acetaminophen tablets expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of… (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

…BITARTRATE AND ACETAMINOPHEN TABLETS Addiction, Abuse, and Misuse Because the use of hydrocodone bitartrate and acetaminophen tablets expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of… (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

…Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine Monoamine Oxidase Inhibitors, Nonselective Beta-Adrenergic Antagonists, or Tricyclic Antidepressants: May produce severe, prolonged… (आर्टिकेन और एड्रेनालिन लेबल, दवाओं के इंटरैक्शन)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

…Cytochrome P450 3A4 Inhibitors and Inducers Concomitant use of hydrocodone bitartrate and acetaminophen tablets with a CYP3A4 inhibitor, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may increase plasma concentrations of hydrocodone bitartrate and acetaminophen tablets and prolong… (हाइड्रोकोडोन और पैरासिटामोल लेबल, चेतावनियां)

Medications for the treatment of hypersensitivity reactions (e.g., acetaminophen, antihistamines, corticosteroids and/or epinephrine) should be available for immediate use in the event of a reaction [see Dosage and Administration (2.10) and Adverse Reactions (6.1) ] . (इन्फ्लिक्सिमैब लेबल, चेतावनियां और सावधानियां)

Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

…Concomitant Use or Discontinuation of Cytochrome P450 3A4 Inhibitors and Inducers Concomitant use of hydrocodone bitartrate and acetaminophen tablets with a CYP3A4 inhibitor, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may increase plasma concentrations of hydrocodone… (हाइड्रोकोडोन और पैरासिटामोल लेबल, चेतावनियां)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Ascorbic acid and acetaminophen may increase plasma ethinyl estradiol concentrations, possibly by inhibition of conjugation. (एटोनोजेस्ट्रेल और एथिनिल एस्ट्राडियोल लेबल, दवाओं के इंटरैक्शन)

…Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine,… (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

These effects could be more pronounced with concomitant use of hydrocodone bitartrate and acetaminophen tablets and both CYP3A4 and CYP2D6 inhibitors, particularly when an inhibitor is added after a stable dose of hydrocodone bitartrate and acetaminophen tablets is achieved [see WARNINGS ]. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (एमिनोफाइलिन लेबल, दवाओं के इंटरैक्शन)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Premedicate patients with an antihistamine and acetaminophen prior to each dose. (एलेमटुज़ुमैब लेबल, चेतावनियां और सावधानियां)

Inform patients also that the central nervous system depressant effects of allopurinol tablets may be additive to those of alcohol and other CNS depressants. (एलोप्यूरिनॉल लेबल, चेतावनियां और सावधानियां)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

The addition of an antipyretic (e.g., acetaminophen) may also be considered [see Dosage and Administration (2.2) ]. (ओक्रेलिज़ुमैब लेबल, चेतावनियां और सावधानियां)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

…Cytochrome P450 3A4 Inhibitors and Inducers Concomitant use of hydrocodone bitartrate and acetaminophen tablets with a CYP3A4 inhibitor, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may increase plasma concentrations of hydrocodone bitartrate and acetaminophen tablets and prolong… (हाइड्रोकोडोन और पैरासिटामोल लेबल, चेतावनियां)

Opioids: Decreased exposure to clopidogrel. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (हाइड्रोकोडोन और पैरासिटामोल लेबल, चेतावनियां)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

…procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine (क्लोरोप्रोकेन लेबल, सावधानियां)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

These effects could be more pronounced with concomitant use of hydrocodone bitartrate and acetaminophen tablets and both CYP3A4 and CYP2D6 inhibitors, particularly when an inhibitor is added after a stable dose of hydrocodone bitartrate and acetaminophen tablets is achieved [see WARNINGS ]. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Prior to the first BIZENGRI infusion, premedicate with a corticosteroid, an H1 antihistamine and acetaminophen to reduce the risk of IRRs [see Dosage and Administration (2.4) ]. (ज़ेनोक्यूटुज़ुमैब लेबल, चेतावनियां और सावधानियां)

These effects could be more pronounced with concomitant use of hydrocodone bitartrate and acetaminophen tablets and both CYP3A4 and CYP2D6 inhibitors, particularly when an inhibitor is added after a stable dose of hydrocodone bitartrate and acetaminophen tablets is achieved [see WARNINGS ]. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

The recent use of other drugs that cause CNS depression or EPS symptoms may also increase the risk; consider reducing the dosage or discontinuing the drug. (ट्राइमेथोबेंज़ामाइड लेबल, चेतावनियां और सावधानियां)

Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (हाइड्रोकोडोन और पैरासिटामोल लेबल, चेतावनियां)

Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Exercise caution when prescribing ZIPSOR with concomitant drugs that are known to be potentially hepatotoxic (e.g., acetaminophen, antibiotics, antiepileptics). (डाइक्लोफेनाक लेबल, चेतावनियां और सावधानियां)

MOTOFEN ® may potentiate the action of barbiturates, tranquilizers, narcotics, and alcohol. (डाइफेनॉक्सिन और एट्रोपिन लेबल, दवाओं के इंटरैक्शन)

Acetaminophen In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen. (डाइफ्लुनिसाल लेबल, दवाओं के इंटरैक्शन)

Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (हाइड्रोकोडोन और पैरासिटामोल लेबल, चेतावनियां)

Ascorbic acid and acetaminophen may increase plasma EE concentrations, possibly by inhibition of conjugation. (डेसोजेस्ट्रेल और एथिनिल एस्ट्राडियोल लेबल, दवाओं के इंटरैक्शन)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (हाइड्रोकोडोन और पैरासिटामोल लेबल, चेतावनियां)

…Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin and carbamazepine). (डेस्मोप्रेसिन लेबल, दवाओं के इंटरैक्शन)

These effects could be more pronounced with concomitant use of hydrocodone bitartrate and acetaminophen tablets and both CYP3A4 and CYP2D6 inhibitors, particularly when an inhibitor is added after a stable dose of hydrocodone bitartrate and acetaminophen tablets is achieved [see WARNINGS ]. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (ड्यूटेट्राबेनाज़िन लेबल, दवाओं के इंटरैक्शन)

Ascorbic acid and acetaminophen may increase plasma EE concentrations, possibly by inhibition of conjugation. (ड्रोस्पिरेनोन और एथिनिल एस्ट्राडियोल लेबल, दवाओं के इंटरैक्शन)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (थियोफाइलिन लेबल, दवाओं के इंटरैक्शन)

The interaction with high-dose fentanyl appears to be due to the combination of nifedipine and a beta-blocker, but the possibility that it may occur with nifedipine alone, with low doses of fentanyl, in other surgical procedures, or with other narcotic analgesics cannot be ruled out. (निफेडिपिन लेबल, चेतावनियां)

These effects could be more pronounced with concomitant use of hydrocodone bitartrate and acetaminophen tablets and both CYP3A4 and CYP2D6 inhibitors, particularly when an inhibitor is added after a stable dose of hydrocodone bitartrate and acetaminophen tablets is achieved [see WARNINGS ]. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Ascorbic acid and acetaminophen may increase plasma ethinyl estradiol levels, possibly by inhibition of conjugation. (नॉरएथिस्टेरोन और एथिनिल एस्ट्राडियोल लेबल, दवाओं के इंटरैक्शन)

Ascorbic acid and acetaminophen may increase plasma EE concentrations, possibly by inhibition of conjugation. (नॉरएल्जेस्ट्रोमिन और एथिनिल एस्ट्राडियोल लेबल, दवाओं के इंटरैक्शन)

Ascorbic acid and acetaminophen may increase plasma EE concentrations, possibly by inhibition of conjugation. (नॉरजेस्टिमेट और एथिनिल एस्ट्राडियोल लेबल, दवाओं के इंटरैक्शन)

Ascorbic acid and acetaminophen may increase plasma EE concentrations, possibly by inhibition of conjugation. (नॉरजेस्ट्रेल और एथिनिल एस्ट्राडियोल लेबल, दवाओं के इंटरैक्शन)

Effects of Other Substances on Acetaminophen Substances that induce or regulate hepatic cytochrome enzyme CYP2E1 may alter the metabolism of acetaminophen and increase its hepatotoxic potential. (पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Opioids: Decreased exposure to prasugrel. (प्रासुग्रेल लेबल, दवाओं के इंटरैक्शन)

…Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine The administration of local anesthetic injections containing epinephrine or norepinephrine to patients receiving monoamine oxidase… (प्रिलोकेन और एड्रेनालिन लेबल, दवाओं के इंटरैक्शन)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (हाइड्रोकोडोन और पैरासिटामोल लेबल, चेतावनियां)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (हाइड्रोकोडोन और पैरासिटामोल लेबल, चेतावनियां)

These effects could be more pronounced with concomitant use of hydrocodone bitartrate and acetaminophen tablets and both CYP3A4 and CYP2D6 inhibitors, particularly when an inhibitor is added after a stable dose of hydrocodone bitartrate and acetaminophen tablets is achieved [see WARNINGS ]. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

In patients on probenecid who require a mild analgesic agent the use of acetaminophen rather than small doses of salicylates would be preferred. (प्रोबेनेसिड लेबल, चेतावनियां)

In patients on probenecid and colchicine who require a mild analgesic agent the use of acetaminophen rather than small doses of salicylates would be preferred. (प्रोबेनेसिड और कोल्चिसिन लेबल, चेतावनियां)

…Concomitant Use or Discontinuation of Cytochrome P450 3A4 Inhibitors and Inducers Concomitant use of hydrocodone bitartrate and acetaminophen tablets with a CYP3A4 inhibitor, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may increase plasma concentrations of hydrocodone… (हाइड्रोकोडोन और पैरासिटामोल लेबल, चेतावनियां)

Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (हाइड्रोकोडोन और पैरासिटामोल लेबल, चेतावनियां)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (हाइड्रोकोडोन और पैरासिटामोल लेबल, चेतावनियां)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (हाइड्रोकोडोन और पैरासिटामोल लेबल, चेतावनियां)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (हाइड्रोकोडोन और पैरासिटामोल लेबल, चेतावनियां)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (हाइड्रोकोडोन और पैरासिटामोल लेबल, चेतावनियां)

Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (हाइड्रोकोडोन और पैरासिटामोल लेबल, चेतावनियां)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (हाइड्रोकोडोन और पैरासिटामोल लेबल, चेतावनियां)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (हाइड्रोकोडोन और पैरासिटामोल लेबल, चेतावनियां)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (हाइड्रोकोडोन और पैरासिटामोल लेबल, चेतावनियां)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (ब्यूपिवाकेन लेबल, चेतावनियां और सावधानियां)

…Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine 7.6 Potent Inhalation Anesthetics Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor… (ब्यूपिवाकेन और एड्रेनालिन लेबल, दवाओं के इंटरैक्शन)

These effects could be more pronounced with concomitant use of hydrocodone bitartrate and acetaminophen tablets and both CYP3A4 and CYP2D6 inhibitors, particularly when an inhibitor is added after a stable dose of hydrocodone bitartrate and acetaminophen tablets is achieved [see WARNINGS ]. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Use with CNS depressants may result in an additive or potentiating effect. (ब्रिमोनिडिन लेबल, दवाओं के इंटरैक्शन)

Use with CNS depressants may result in an additive or potentiating effect. (ब्रिमोनिडिन और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

…Cytochrome P450 3A4 Inhibitors and Inducers Concomitant use of hydrocodone bitartrate and acetaminophen tablets with a CYP3A4 inhibitor, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may increase plasma concentrations of hydrocodone bitartrate and acetaminophen tablets and prolong… (हाइड्रोकोडोन और पैरासिटामोल लेबल, चेतावनियां)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (हाइड्रोकोडोन और पैरासिटामोल लेबल, चेतावनियां)

Concurrent use of metyrosine with alcohol or other CNS depressants can increase their sedative effects. (मेटाइरोसिन लेबल, दवाओं के इंटरैक्शन)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

…procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine (मेपिवाकेन लेबल, दवाओं के इंटरैक्शन)

Premedicate with an analgesic medication (e.g., acetaminophen) prior to each APHEXDA dose. (मोटिक्साफोर्टाइड लेबल, चेतावनियां और सावधानियां)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (हाइड्रोकोडोन और पैरासिटामोल लेबल, चेतावनियां)

Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Isoflurane and enflurane may also prolong the duration of action of initial and maintenance doses of Rocuronium Bromide Injection and decrease the average infusion requirement of Rocuronium Bromide Injection by 40% compared to opioid/nitrous oxide/oxygen anesthesia. (रोक्यूरोनियम लेबल, दवाओं के इंटरैक्शन)

…Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine NAROPIN should be used with caution in patients receiving other local anesthetics or agents structurally related to amide- type… (रोपिवाकेन लेबल, दवाओं के इंटरैक्शन)

These effects could be more pronounced with concomitant use of hydrocodone bitartrate and acetaminophen tablets and both CYP3A4 and CYP2D6 inhibitors, particularly when an inhibitor is added after a stable dose of hydrocodone bitartrate and acetaminophen tablets is achieved [see WARNINGS ]. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

…Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine 7.6 Potent Inhalation Anesthetics Serious dose-related cardiac arrhythmias may occur if preparations containing epinephrine are… (लिडोकेन और एड्रेनालिन लेबल, दवाओं के इंटरैक्शन)

…prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, isofamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sufonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine (लिडोकेन और प्रिलोकेन लेबल, दवाओं के इंटरैक्शन)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Methadone Diphenylheptane opioids (e.g., methadone) have been shown in nonclinical studies to dose-dependently reduce the activation of ClC-2 by lubiprostone in the gastrointestinal tract. (लुबिप्रोस्टोन लेबल, दवाओं के इंटरैक्शन)

Ascorbic acid and acetaminophen may increase systemic exposure of ethinyl estradiol, possibly by inhibition of conjugation. (लेवोनॉरजेस्ट्रेल और एथिनिल एस्ट्राडियोल लेबल, दवाओं के इंटरैक्शन)

Caution should be exercised when JUXTAPID is used with other medications known to have potential for hepatotoxicity, such as isotretinoin, amiodarone, acetaminophen (>4 g/day for ≥3 days/week), methotrexate, tetracyclines, and tamoxifen. (लोमिटापाइड लेबल, चेतावनियां और सावधानियां)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

…Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine,… (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (हाइड्रोकोडोन और पैरासिटामोल लेबल, चेतावनियां)

These effects could be more pronounced with concomitant use of hydrocodone bitartrate and acetaminophen tablets and both CYP3A4 and CYP2D6 inhibitors, particularly when an inhibitor is added after a stable dose of hydrocodone bitartrate and acetaminophen tablets is achieved [see WARNINGS ]. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (हाइड्रोकोडोन और पैरासिटामोल लेबल, चेतावनियां)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (हाइड्रोकोडोन और पैरासिटामोल लेबल, चेतावनियां)

Aspirin/Acetaminophen No drug-drug interactions have been demonstrated between argatroban and concomitantly administered aspirin or acetaminophen [ see Clinical Pharmacology (12.3) ]. (आर्गाट्रोबैन लेबल, दवाओं के इंटरैक्शन)

Orally Administered Drugs (e.g., acetaminophen) Clinical Impact Exenatide slows gastric emptying. (एक्सेनाटाइड लेबल, दवाओं के इंटरैक्शन)

The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (एपोएटिन अल्फा लेबल, चेतावनियां और सावधानियां)

Interaction With Laboratory or Diagnostic Testing Some quinolones, including ofloxacin, may produce false-positive urine screening results for opiates using commercially available immunoassay kits. (ओफ्लॉक्सासिन लेबल, सावधानियां)

Other Drugs: Co-administration of telmisartan did not result in a clinically significant interaction with acetaminophen, amlodipine, glyburide, simvastatin, hydrochlorothiazide, warfarin, or ibuprofen. (टेल्मिसार्टन और एम्लोडिपिन लेबल, दवाओं के इंटरैक्शन)

Effect of Other Drugs on Treprostinil Drug interaction studies have been carried out with treprostinil (oral or subcutaneous) co-administered with acetaminophen (4 g/day), warfarin (25 mg/day), and fluconazole (200 mg/day), respectively, in healthy volunteers. (ट्रेप्रोस्टिनिल लेबल, दवाओं के इंटरैक्शन)

Antihistamines Amphetamines may counteract the sedative effect of antihistamines. (डेक्सट्रोएम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

In Postanesthetic Use Doxapram is neither an antagonist to muscle relaxant drugs nor a specific narcotic antagonist. (डॉक्साप्राम लेबल, चेतावनियां)

Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen. (डोब्यूटामिन लेबल, दवाओं के इंटरैक्शन)

Narcotics: Exacerbation of bradycardia possible. (पाइरिडोस्टिग्मिन लेबल, दवाओं के इंटरैक्शन)

Anaphylaxis and Other Hypersensitivity Reactions Acetaminophen There have been postmarketing reports of hypersensitivity and anaphylaxis associated with the use of acetaminophen. (पैरासिटामोल और आइबुप्रोफेन लेबल, चेतावनियां और सावधानियां)

…to date with the following: (1) cardiac glycosides– digitalis and digoxin; (2) hypoglycemics–insulin, chlorpropamide, phenformin, tolazamide, and tolbutamide; (3) tranquilizers and sedatives–chlordiazepoxide, diazepam, and phenobarbital; (4) antigout–allopurinol, colchicine, and probenecid; (5) antiarrhythmics–procainamide, propranolol (see WARNINGS however),… (प्राज़ोसिन लेबल, दवाओं के इंटरैक्शन)

Other Concomitant Therapy Although specific interaction studies were not performed, PROSCAR was concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, α-blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA… (फिनास्टेराइड लेबल, दवाओं के इंटरैक्शन)

Premedicate patients with an antihistamine and acetaminophen prior to dosing. (रिटुक्सिमैब लेबल, चेतावनियां और सावधानियां)

Patients with Grade 1 and 2 TFR may also be treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms. (लेनालिडोमाइड लेबल, चेतावनियां और सावधानियां)

Interactions with Laboratory or Diagnostic Testing Some fluoroquinolones, including Levofloxacin in 5% Dextrose Injection, may produce false-positive urine screening results for opiates using commercially available immunoassay kits. (लेवोफ्लॉक्सासिन लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Probenecid Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline,… (सिडोफोविर लेबल, दवाओं के इंटरैक्शन)

No clinically significant drug interactions have been observed between RPV and the following medications: acetaminophen, atorvastatin, chlorzoxazone, ethinyl estradiol, ledipasvir/sofosbuvir, norethindrone, sildenafil, simeprevir, sofosbuvir, sofosbuvir/velpatasvir, sofosbuvir/velpatasvir/voxilaprevir, or TDF. (एमट्रिसिटाबिन, रिल्पिविरिन और टेनोफोविर लेबल, दवाओं के इंटरैक्शन)

…Clinically Significant Drug Interaction with TAMIFLU No dose adjustments are needed for either oseltamivir or the concomitant drug when coadministering oseltamivir with amoxicillin, acetaminophen, aspirin, cimetidine, antacids (magnesium and aluminum hydroxides and calcium carbonates), rimantadine, amantadine, or warfarin [see Clinical Pharmacology (12.3) ] . (ओसेल्टामिविर लेबल, दवाओं के इंटरैक्शन)

…adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology (12.3) ]. (मोंटेलुकास्ट लेबल, दवाओं के इंटरैक्शन)

Based on these data, ISENTRESS is not expected to affect the pharmacokinetics of drugs that are substrates of these enzymes or P-glycoprotein (e.g., protease inhibitors, NNRTIs, opioid analgesics, statins, azole antifungals, proton pump inhibitors and anti-erectile dysfunction agents). (राल्टेग्राविर लेबल, दवाओं के इंटरैक्शन)

…included in Table 6, the interaction between EDURANT and the following drugs was evaluated in clinical studies and no dose adjustment is needed for either drug [see Clinical Pharmacology (12.3) ] : acetaminophen, atorvastatin, chlorzoxazone, cabotegravir, ethinylestradiol, norethindrone, raltegravir, sildenafil, simeprevir and tenofovir disoproxil fumarate. (रिल्पिविरिन लेबल, दवाओं के इंटरैक्शन)

Acetaminophen Acetaminophen had no effect on the plasma levels of sulindac or its sulfide metabolite. (सुलिंडैक लेबल, दवाओं के इंटरैक्शन)